EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Genetic risk classification for adults with AML receiving less-intensive therapies: the 2024 ELN recommendations

Hartmut Döhner iD, Courtney D DiNardo iD, Frederick R Appelbaum, Charles Craddock iD, Hervé Dombret, Benjamin L Ebert iD, Pierre Fenaux, Lucy A Godley, Robert P Hasserjian, Richard A Larson iD, Ross L Levine, Yasushi Miyazaki und 11 weitere

Blood · 21.11.2024 · 144 (21) · 2169-2173

DOI: 10.1182/blood.2024025409 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Blood, erschienen am 21.11.2024. Verfasst von Hartmut Döhner und 22 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine III, Ulm University Hospital, Ulm, Germany. Hauptthemen laut MEDLINE: Leukemia, Myeloid, Acute. Die Arbeit wurde bisher 282-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The European LeukemiaNet (ELN) genetic risk classifications were developed based on data from younger adults receiving intensive chemotherapy. Emerging analyses from patients receiving less-intensive therapies prompted a proposal for an ELN genetic risk classification specifically for this patient population.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Leukemia, Myeloid, AcuteHumansAdultRisk AssessmentGenetic Predisposition to DiseaseRisk Factors

Autor:innen und Institutionen

  • Department of Internal Medicine III, Ulm University Hospital, Ulm, Germany.
  • Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX.
  • Division of Hematology and Oncology, University of Washington and Fred Hutchinson Cancer Research Center, Seattle, WA.
  • University of Warwick Trials Unit, Centre for Clinical Haematology, Queen Elizabeth Hospital, Birmingham, United Kingdom.
  • Department of Hematology, Saint-Louis Institute for Research, Université Paris Cité, Hôpital Saint-Louis, Assistance Publique-Hôpitaux de Paris, Paris, France.
  • Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.

ORCID-Profile: Hartmut Döhner, Courtney D DiNardo, Charles Craddock, Benjamin L Ebert, Richard A Larson, Dietger Niederwieser, Christoph Röllig, Jorge Sierra, Jianxiang Wang, Agnieszka Wierzbowska, Andrew H Wei, Bob Löwenberg

Zitieren

APA

Döhner, H., DiNardo, C. D., Appelbaum, F. R., Craddock, C., Dombret, H., Ebert, B. L., Fenaux, P., Godley, L. A., Hasserjian, R. P., Larson, R. A., Levine, R. L., Miyazaki, Y., Niederwieser, D., Ossenkoppele, G., Röllig, C., Sierra, J., Stein, E. M., Tallman, M. S., Tien, H. F., …, & Löwenberg, B. (2024). Genetic risk classification for adults with AML receiving less-intensive therapies: the 2024 ELN recommendations. Blood, 144(21), 2169-2173. https://doi.org/10.1182/blood.2024025409

Vancouver

Döhner H, DiNardo CD, Appelbaum FR, Craddock C, Dombret H, Ebert BL, et al. Genetic risk classification for adults with AML receiving less-intensive therapies: the 2024 ELN recommendations. Blood. 2024;144(21):2169-2173. doi:10.1182/blood.2024025409

BibTeX
@article{Dhner2024,
  author = {Döhner, Hartmut and DiNardo, Courtney D and Appelbaum, Frederick R and Craddock, Charles and Dombret, Hervé and Ebert, Benjamin L and Fenaux, Pierre and Godley, Lucy A and Hasserjian, Robert P and Larson, Richard A and Levine, Ross L and Miyazaki, Yasushi and Niederwieser, Dietger and Ossenkoppele, Gert and Röllig, Christoph and Sierra, Jorge and Stein, Eytan M and Tallman, Martin S and Tien, Hwei-Fang and Wang, Jianxiang and Wierzbowska, Agnieszka and Wei, Andrew H and Löwenberg, Bob},
  title = {Genetic risk classification for adults with AML receiving less-intensive therapies: the 2024 ELN recommendations},
  journal = {Blood},
  year = {2024},
  volume = {144},
  number = {21},
  pages = {2169--2173},
  doi = {10.1182/blood.2024025409}
}
Kostenlos starten →